Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle. 

Polifarmacia en adultos mayores ¿Qué medicación no podemos suspender?

Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should we discontinue when it means risking patient health? This study recently presented at JAMA at least clarifies what drug NEVER to discontinue. 

The study looked at a cohort of 29,047 patients older than 65 who were on statins, hypertensive medication, antidiabetics and antiplatelets between 2013 and 2015.

This study was particularly focused on patients discontinuing statins. These were matched using propensity score to be compared against patients who stayed on all medication (statins and the rest). 

Of the total population of nearly 30,000 patients, 20% discontinued statins and kept taking the rest of prescribed medication; the rest of the population kept taking all drugs and served as control group. 

Patients discontinuing statins had higher risk of hospitalization for cardiac failure (HR 1.24; CI 95%, 1.07-1.43), any adverse cardiovascular event (HR, 1.14; CI 95%, 1.03-1.26), all cause death (HR, 1.15; CI 95%, 1.02-1.30) and emergency hospitalization for any cause (HR, 1.12; CI 95%, 1.05-1.19). 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


Comorbidities rate resulted very similar in both groups, which makes it hard to believe doctors would discontinue statins because of patient frailty. 

Conclusion

Patients receiving polypharmacy who for whatever reason discontinue statins (while still taking the rest of prescribed drugs) present increased risk of fatal and non-fatal events. 

Original Title: Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy.

Reference: Federico Rea et al. JAMA Netw Open. 2021 Jun 1;4(6):e2113186. doi: 10.1001/jamanetworkopen.2021.13186.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...